ASC Therapeutics

Quick facts

Phase 2 pipeline

• ASC930
  ASC930 is a small molecule that targets the [insert target here, if known].

Phase 1 pipeline

• ASC618

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ASC Therapeutics portfolio CI brief
• ASC Therapeutics pipeline updates RSS

Related

• Sector hub: All tracked pharma companies